Monash IVF, a $236 million ASX-listed Australian fertility company, is facing intense scrutiny following two significant embryo transplant errors.

The company admitted to a bungled embryo implant at its Melbourne clinic, which came shortly after a similar incident in Queensland where a woman gave birth to another woman's child due to an incorrect embryo transfer.

The recent mix-up involved a woman being impregnated with her own embryo instead of her same-sex partner's, prompting an internal investigation and an expansion of an independent review related to the previous incident.

In light of these events, CEO Michael Knaap has resigned, and Malik Jainudeen, the chief financial officer, has been appointed as the interim CEO.

Monash IVF has publicly apologized to the affected couple and is providing them with support as part of its response to the incidents.

To restore confidence, Monash IVF is enhancing its verification processes and patient safeguards to prevent future incidents.

Currently, IVF practices in Australia are regulated by state and territory laws, leading to inconsistencies across the nation.

Fertility researcher Prof Jeremy Thompson has highlighted a global shortage of skilled embryologists, which may contribute to errors in the field.

Monash IVF has notified relevant regulators and its insurers about the incident, expecting it to be covered by insurance.

Following the news of the incident, Monash IVF's shares dropped 25% to a near five-year low but later recovered slightly after a 7% increase.

Experts are advocating for a unified national framework for assisted reproductive technology (ART) and the establishment of an independent authority to enhance oversight and trust in the sector.

There are increasing calls for stricter compliance and registration of embryologists under a national scheme to ensure accountability and prevent future mishaps.